Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mavuto Mukaka

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Antimicrobial Agents and Chemotherapy|September 13, 2021
Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong SubregionMallika Imwong, Kanokon Suwannasin, Suttipat Srisutham, et al.
Ebiomedicine|September 27, 2023
Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malariaMavuto Mukaka, Marie A Onyamboko, Peter Olupot-Olupot, et al.
The New England Journal of Medicine|March 1, 2023
Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub TyphusGeorge M Varghese, Divya Dayanand, Karthik Gunasekaran, et al.
The Lancet. Infectious Diseases|March 11, 2022
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trialThomas J Peto, Rupam Tripura, James J Callery, et al.
Plos One|February 6, 2020
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trialsKoukeo Phommasone, Frank van Leth, Thomas J Peto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2018
Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label TrialKatherine Plewes, Hugh W F Kingston, Aniruddha Ghose, et al.
BMC Medicine|January 20, 2018
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan AfricaW Robert Taylor, Htee Khu Naw, Kathryn Maitland, et al.
Wellcome Open Research|November 13, 2023
Mixed methods study protocol for combining stakeholder-led rapid evaluation with near real-time continuous registry data to facilitate evaluations of quality of care in intensive care units, Aasiyah Rashan, Abi Beane, et al.
Wellcome Open Research|March 21, 2022
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness projectArjun Chandna, Rusheng Chew, Nan Shwe Nwe Htun, et al.
The Lancet. Infectious Diseases|July 27, 2019
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic studyRob W van der Pluijm, Mallika Imwong, Nguyen Hoang Chau, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Antimicrobial Agents and Chemotherapy|September 13, 2021
Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong SubregionMallika Imwong, Kanokon Suwannasin, Suttipat Srisutham, et al.
Ebiomedicine|September 27, 2023
Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malariaMavuto Mukaka, Marie A Onyamboko, Peter Olupot-Olupot, et al.
The New England Journal of Medicine|March 1, 2023
Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub TyphusGeorge M Varghese, Divya Dayanand, Karthik Gunasekaran, et al.
The Lancet. Infectious Diseases|March 11, 2022
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trialThomas J Peto, Rupam Tripura, James J Callery, et al.
Plos One|February 6, 2020
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trialsKoukeo Phommasone, Frank van Leth, Thomas J Peto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2018
Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label TrialKatherine Plewes, Hugh W F Kingston, Aniruddha Ghose, et al.
BMC Medicine|January 20, 2018
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan AfricaW Robert Taylor, Htee Khu Naw, Kathryn Maitland, et al.
Wellcome Open Research|November 13, 2023
Mixed methods study protocol for combining stakeholder-led rapid evaluation with near real-time continuous registry data to facilitate evaluations of quality of care in intensive care units, Aasiyah Rashan, Abi Beane, et al.
Wellcome Open Research|March 21, 2022
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness projectArjun Chandna, Rusheng Chew, Nan Shwe Nwe Htun, et al.
The Lancet. Infectious Diseases|July 27, 2019
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic studyRob W van der Pluijm, Mallika Imwong, Nguyen Hoang Chau, et al.
Pageof 15